Comprehensive Stock Comparison
Compare argenx SE (ARGX) vs Kymera Therapeutics, Inc. (KYMR) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | ARGX | 78.6% revenue growth vs KYMR's -16.7% |
| Quality / Margins | ARGX | 23.3% net margin vs KYMR's -7.9% |
| Stability / Safety | ARGX | Beta 0.44 vs KYMR's 1.31, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | KYMR | +191.4% vs ARGX's +22.8% |
| Efficiency (ROA) | ARGX | 12.9% ROA vs KYMR's -17.9%, ROIC -0.5% vs -24.9% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
argenx is a biotechnology company that develops antibody-based therapies for autoimmune diseases. It generates nearly all its revenue from VYVGART — its FcRn blocker for conditions like myasthenia gravis — with additional income from partnerships and licensing. The company's key advantage is its proprietary antibody engineering platform that creates differentiated therapies with potentially better safety and efficacy profiles.
Kymera Therapeutics is a biopharmaceutical company developing targeted protein degraders — small molecules that harness the body's natural protein degradation system to eliminate disease-causing proteins. It generates revenue primarily through strategic partnerships and milestone payments from pharmaceutical collaborators — with potential future revenue from drug sales if clinical candidates succeed. The company's key advantage is its proprietary Pegasus platform for discovering novel protein degraders, which targets previously "undruggable" proteins and creates a pipeline of first-in-class therapies.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
ARGX leads in 2 of 6 categories (Financial Metrics, Profitability & Efficiency). KYMR leads in 2 (Valuation Metrics, Total Returns). 1 tied.
Financial Metrics (TTM)
ARGX is the larger business by revenue, generating $4.0B annually — 100.9x KYMR's $39M. ARGX is the more profitable business, keeping 23.3% of every revenue dollar as net income compared to KYMR's -7.9%. On growth, ARGX holds the edge at +5.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ARGXargenx SE | KYMRKymera Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $4.0B | $39M |
| EBITDAEarnings before interest/tax | $95M | -$349M |
| Net IncomeAfter-tax profit | $923M | -$311M |
| Free Cash FlowCash after capex | $213M | -$234M |
| Gross MarginGross profit ÷ Revenue | +75.5% | +100.0% |
| Operating MarginEBIT ÷ Revenue | -1.0% | -8.9% |
| Net MarginNet income ÷ Revenue | +23.3% | -7.9% |
| FCF MarginFCF ÷ Revenue | +5.4% | -6.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +5.1% | -61.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +12.6% | -11.4% |
Valuation Metrics
| Metric | ARGXargenx SE | KYMRKymera Therapeuti… |
|---|---|---|
| Market CapShares × price | $47.5B | $7.4B |
| Enterprise ValueMkt cap + debt − cash | $46.0B | $7.2B |
| Trailing P/EPrice ÷ TTM EPS | 60.01x | -24.76x |
| Forward P/EPrice ÷ next-FY EPS est. | 25.57x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 21.67x | 189.51x |
| Price / BookPrice ÷ Book value/share | 9.09x | 4.88x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
ARGX delivers a 15.1% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-20 for KYMR. ARGX carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to KYMR's 0.05x. On the Piotroski fundamental quality scale (0–9), KYMR scores 4/9 vs ARGX's 3/9, reflecting mixed financial health.
| Metric | ARGXargenx SE | KYMRKymera Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | +15.1% | -19.7% |
| ROA (TTM)Return on assets | +12.9% | -17.9% |
| ROICReturn on invested capital | -0.5% | -24.9% |
| ROCEReturn on capital employed | -0.4% | -27.2% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 0.05x |
| Net DebtTotal debt minus cash | -$1.5B | -$275M |
| Cash & Equiv.Liquid assets | $1.5B | $357M |
| Total DebtShort + long-term debt | $39M | $82M |
| Interest CoverageEBIT ÷ Interest expense | 166.64x | -1403.21x |
Total Returns (with DRIP)
A $10,000 investment in ARGX five years ago would be worth $22,521 today (with dividends reinvested), compared to $18,851 for KYMR. Over the past 12 months, KYMR leads with a +191.4% total return vs ARGX's +22.8%. The 3-year compound annual growth rate (CAGR) favors KYMR at 42.8% vs ARGX's 28.0% — a key indicator of consistent wealth creation.
| Metric | ARGXargenx SE | KYMRKymera Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | -8.7% | +25.5% |
| 1-Year ReturnPast 12 months | +22.8% | +191.4% |
| 3-Year ReturnCumulative with dividends | +109.5% | +191.1% |
| 5-Year ReturnCumulative with dividends | +125.2% | +88.5% |
| 10-Year ReturnCumulative with dividends | +3234.4% | +174.7% |
| CAGR (3Y)Annualised 3-year return | +28.0% | +42.8% |
Risk & Volatility
ARGX is the less volatile stock with a 0.44 beta — it tends to amplify market swings less than KYMR's 1.31 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KYMR currently trades 88.7% from its 52-week high vs ARGX's 82.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ARGXargenx SE | KYMRKymera Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.44x | 1.31x |
| 52-Week HighHighest price in past year | $934.62 | $103.00 |
| 52-Week LowLowest price in past year | $510.06 | $19.45 |
| % of 52W HighCurrent price vs 52-week peak | +82.1% | +88.7% |
| RSI (14)Momentum oscillator 0–100 | 33.9 | 77.9 |
| Avg Volume (50D)Average daily shares traded | 301K | 620K |
Analyst Outlook
Wall Street rates ARGX as "Buy" and KYMR as "Buy". Consensus price targets imply 33.9% upside for ARGX (target: $1027) vs 28.4% for KYMR (target: $117).
| Metric | ARGXargenx SE | KYMRKymera Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $1026.71 | $117.31 |
| # AnalystsCovering analysts | 35 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Sep 20 | Feb 26 | Change |
|---|---|---|---|
| argenx SE (ARGX) | 100 | 368.37 | +268.4% |
| Kymera Therapeutics… (KYMR) | 93.69 | 227.36 | +142.7% |
argenx SE (ARGX) returned +125% over 5 years vs Kymera Therapeutics… (KYMR)'s +89%. A $10,000 investment in ARGX 5 years ago would be worth $22,521 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| argenx SE (ARGX) | $15M | $2.2B | +14054.3% |
| Kymera Therapeutics… (KYMR) | $0.00 | $39M | — |
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| argenx SE (ARGX) | -145.3% | 38.0% | +126.2% |
| Kymera Therapeutics… (KYMR) | -14.1% | -7.9% | +43.6% |
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| argenx SE (ARGX) | -1.2 | 12.78 | +1165.0% |
| Kymera Therapeutics… (KYMR) | -0.48 | -3.69 | -668.8% |
Chart 5Free Cash Flow — 5 Years
argenx SE generated $-151M FCF in 2024 (+79% vs 2021). Kymera Therapeutics, Inc. generated $-234M FCF in 2025 (-80% vs 2021).
ARGX vs KYMR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is ARGX or KYMR a better buy right now?
argenx SE (ARGX) offers the better valuation at 60.0x trailing P/E (25.6x forward), making it the more compelling value choice. Analysts rate argenx SE (ARGX) a "Buy" — based on 35 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ARGX or KYMR?
Over the past 5 years, argenx SE (ARGX) delivered a total return of +125.2%, compared to +88.5% for Kymera Therapeutics, Inc. (KYMR). A $10,000 investment in ARGX five years ago would be worth approximately $23K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ARGX returned +32.3% versus KYMR's +174.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ARGX or KYMR?
By beta (market sensitivity over 5 years), argenx SE (ARGX) is the lower-risk stock at 0.44β versus Kymera Therapeutics, Inc.'s 1.31β — meaning KYMR is approximately 199% more volatile than ARGX relative to the S&P 500. On balance sheet safety, argenx SE (ARGX) carries a lower debt/equity ratio of 1% versus 5% for Kymera Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — ARGX or KYMR?
argenx SE (ARGX) is the more profitable company, earning 38.0% net margin versus -794.4% for Kymera Therapeutics, Inc. — meaning it keeps 38.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARGX leads at -1.0% versus -891.3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is ARGX or KYMR more undervalued right now?
Analyst consensus price targets imply the most upside for ARGX: 33.9% to $1026.71.
06Which pays a better dividend — ARGX or KYMR?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is ARGX or KYMR better for a retirement portfolio?
For long-horizon retirement investors, argenx SE (ARGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.44)). Both have compounded well over 10 years (ARGX: +32.3%, KYMR: +174.7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between ARGX and KYMR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.